Tivic Health FY 2023 revenue down 36% to $1.2M; net loss narrows to $8.2M

Valion Bio, Inc.

Revenue $1.2M (-36% YoY) on 52% fewer unit sales; ASP up 46%.
Net loss improved to $8.2M from $10.1M; cash $3.4M, no debt.
Raised $7.9M via two public offerings in 2023; executed 1-for-100 reverse split and regained Nasdaq compliance.
Completed enrollment for VNS pilot study in Feb 2024; results pending.
Named to Fast Company's Most Innovative Companies 2023 in Medical Device.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Valion Bio, Inc. reported the year ending December 31, 2023 results: revenue $1.2M, net income net loss was $8.2M.

Period: the year ending December 31, 2023
Revenue: $1.2M
Net income: net loss was $8.2M
Result: reported results

Exact text from the filing

and Global Health & Pharma (GHP) named Tivic Health the Most Pioneering Bioelectronic Medicine Company. 2023 Financial Performance • Revenue (net of returns) for 2023 was $1.2M compared to $1.8M for the year ended December 31, 2022. The decrease of $664 thousand, or 36%, was due to a 52% decrease in ClearUP unit sales, offset by 46% higher average

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-036006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.